Claims
- 1. A compound selected from the group consisting of: ##STR214## and pharmaceutically acceptable salts thereof.
- 2. A compound of claim 1 which is ##STR215##
- 3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 4. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.
CROSS-REFERENCE
This is a continuation of Ser. No. 08/168,897, filed Dec. 16, 1993, which is a division of application Ser. No. 07/860,747, filed Mar. 25, 1992, now U.S. Pat. No. 5,292,756, which is a continuation-in-part of U.S. Ser. No. 07/750,647, filed Aug. 30, 1991, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/589,130, filed Sep. 27, 1990, now abandoned.
US Referenced Citations (11)
Foreign Referenced Citations (4)
Number |
Date |
Country |
0 004 011 |
Feb 1979 |
EPX |
0 381 033 |
Aug 1990 |
EPX |
0 384 362 |
Aug 1990 |
EPX |
0 449 079 |
Mar 1991 |
EPX |
Non-Patent Literature Citations (4)
Entry |
Hsia et al. "A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plaminogen activator for acute myocardial infarction" N. Eng. J. Med. v. 323 p. 1433-1437 Nov. 1990. |
Merck Index, Tiropramide, 10th Ed., paragraph 9301 (1979). |
Ruoslahti et al., Science, vol. 238, pp. 491-497 (1987). |
Shebuski, R.J., "Principles Underlying the Use of Conjunctive Agents with Plasminogen Activators", Annals New York Academy of Sciences, vol. 667, pp. 382-394 (1991). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
860747 |
Mar 1992 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
168897 |
Dec 1993 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
750647 |
Aug 1991 |
|
Parent |
589130 |
Sep 1990 |
|